Clinical-decision criteria to identify recurrent diabetic macular edema patients suitable for fluocinolone acetonide implant therapy (Iluvien®) and follow-up considerations/ recommendations

Adán, A. ; Cabrera, F. ; Figueroa, M.S. ; Cervera, E. ; Ascaso, F.J. (Universidad de Zaragoza) ; Udaondo, P. ; Abraldes, M. ; Reyes, M.Á. ; Pazos, M. ; Pessoa, B. ; Armadá, F.

Resumen: Current management of diabetic macular edema (DME) predominantly involves treatment with short-acting intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) and/or corticosteroids; however, short-acting therapies (lasting between 1 and 6 months) require frequent injections to maintain efficacy, meaning a considerable treatment burden for diabetic patients with multiple comorbidities. Continuous injections needed in some cases are an economic burden for patients/healthcare system, so real-life clinical practice tends to adopt a reactive approach, ie, watch and wait for worsening symptoms, which consequently increases the risk of undertreatment and edema recurrence. On March 7th 2019, a group of experts in retinal medicine and surgery held a roundtable meeting in Madrid, Spain to discuss how to (1) optimize clinical outcomes through earlier use of fluocinolone acetonide (FAc) implant (ILUVIEN®) in patients with persistent or recurrent DME despite therapy; and, (2) to provide guidance to assist physicians in deciding which patients should be treated with ILUVIEN. In this regard, a 36-month follow-up consensus protocol is presented. In conclusion, patients that achieve a complete or partial anatomical, and preferably functional, response following one or two intravitreal dexametha-sone implants, but with recurrence of edema after 3–4 months, are deemed by the authors most likely to benefit from ILUVIEN, and the switch to FAc implant should not be delayed more than 12 months after the initiation of at least the first dexamethasone implant.

Idioma: Inglés

DOI: 10.2147/OPTH.S252359

Año: 2020

Publicado en: Clinical Ophthalmology 14 (2020), 2091-2107
ISSN: 1177-5467

Factor impacto SCIMAGO: 1.024 - Ophthalmology (Q2)

Tipo y forma: Revisión (Versión definitiva)

Área (Departamento): Área Oftalmología (Dpto. Cirugía)